344 related articles for article (PubMed ID: 29852782)
21. Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach.
Tsukamoto H; Mizoshita T; Sasaki M; Mizushima T; Tanida S; Ozeki K; Hirata Y; Shimura T; Kataoka H; Kamiya T; Nojiri S; Tsukamoto T; Tatematsu M; Joh T
Asian Pac J Cancer Prev; 2011; 12(4):1049-54. PubMed ID: 21790250
[TBL] [Abstract][Full Text] [Related]
22. [Gastroesophageal reflux disease: pathogenetic basis of differentiated tactics of treatment].
Tkachenko EI; Uspenskiĭ IuP; Karateev AE; Bakulin IG; Pakhomova IG
Eksp Klin Gastroenterol; 2009; (2):104-14. PubMed ID: 19552028
[TBL] [Abstract][Full Text] [Related]
23. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.
Ko Y; Tang J; Sanagapalli S; Kim BS; Leong RW
Expert Opin Drug Saf; 2016 Jan; 15(1):53-63. PubMed ID: 26560097
[TBL] [Abstract][Full Text] [Related]
24. [Effect of H2-receptor antagonist and proton pomp inhibitor on the treatment of acid-related disease].
Kawai T; Yagi K; Moriyasu F
Nihon Rinsho; 2015 Jul; 73(7):1159-62. PubMed ID: 26165073
[TBL] [Abstract][Full Text] [Related]
25. Helicobacter gastritis induces changes in the oxyntic mucosa indistinguishable from the effects of proton pump inhibitors.
Kumar KR; Iqbal R; Coss E; Park C; Cryer B; Genta RM
Hum Pathol; 2013 Dec; 44(12):2706-10. PubMed ID: 24071014
[TBL] [Abstract][Full Text] [Related]
26. Drugs for peptic ulcer disease and GERD.
Treat Guidel Med Lett; 2011 Sep; 9(109):55-60; quiz 2 p following 60. PubMed ID: 21860368
[No Abstract] [Full Text] [Related]
27. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations.
Koyyada A
Therapie; 2021; 76(1):13-21. PubMed ID: 32718584
[TBL] [Abstract][Full Text] [Related]
28. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
[TBL] [Abstract][Full Text] [Related]
29. Role of proton pump inhibitors in preventing hypergastrinemia-associated carcinogenesis and in antagonizing the trophic effect of gastrin.
Han YM; Park JM; Kangwan N; Jeong M; Lee S; Cho JY; Ko WJ; Hahm KB
J Physiol Pharmacol; 2015 Apr; 66(2):159-67. PubMed ID: 25903947
[TBL] [Abstract][Full Text] [Related]
30. Drugs, bugs, and esophageal pH profiles.
Robinson M
Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic approaches to reflux disease, focusing on acid secretion.
Kinoshita Y; Adachi K; Fujishiro H
J Gastroenterol; 2003 Mar; 38 Suppl 15():13-9. PubMed ID: 12698865
[TBL] [Abstract][Full Text] [Related]
32. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
Inatomi N; Matsukawa J; Sakurai Y; Otake K
Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
[TBL] [Abstract][Full Text] [Related]
33. [Indications and consequences of Helicobacter pylori eradication on gastroesophageal reflux disease].
Gisbert JP; Piqué JM
Med Clin (Barc); 2005 May; 124(18):697-709. PubMed ID: 15899166
[TBL] [Abstract][Full Text] [Related]
34. Prospective Study of Gastroesophageal Reflux, Use of Proton Pump Inhibitors and H2-Receptor Antagonists, and Risk of Hearing Loss.
Lin BM; Curhan SG; Wang M; Jacobson BC; Eavey R; Stankovic KM; Curhan GC
Ear Hear; 2017; 38(1):21-27. PubMed ID: 27556519
[TBL] [Abstract][Full Text] [Related]
35. Problems Associated with Deprescribing of Proton Pump Inhibitors.
Helgadottir H; Bjornsson ES
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31684070
[TBL] [Abstract][Full Text] [Related]
36. Adverse events of HP eradication: long-term negative consequences of HP eradication.
Koster ED
Acta Gastroenterol Belg; 1998; 61(3):350-1. PubMed ID: 9795471
[TBL] [Abstract][Full Text] [Related]
37. [Current use of proton pump inhibitors and when to limit, stop or not start treatment].
Helgadottir H; Bjornsson ES
Laeknabladid; 2023 Jul; 109(708):338-345. PubMed ID: 37378651
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological management of gastro-oesophageal reflux disease.
Klinkenberg-Knol EC; Festen HP; Meuwissen SG
Drugs; 1995 May; 49(5):695-710. PubMed ID: 7601011
[TBL] [Abstract][Full Text] [Related]
39. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions?
Eslami L; Nasseri-Moghaddam S
Arch Iran Med; 2013 Aug; 16(8):449-58. PubMed ID: 23906249
[TBL] [Abstract][Full Text] [Related]
40. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
Mattos ÂZ; Marchese GM; Fonseca BB; Kupski C; Machado MB
Arq Gastroenterol; 2017 Dec; 54(4):271-280. PubMed ID: 28954042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
